TrialJournal of cancer research and clinical oncology2023

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).

Radoslav Chekerov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.